2005
DOI: 10.1200/jco.2005.09.017
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: This meta-analysis showed that postoperative adjuvant chemotherapy with UFT was associated with improved 5- and 7-year survival in a Japanese patient population composed primarily of stage I adenocarcinoma patients.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

3
129
1
6

Year Published

2006
2006
2023
2023

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 239 publications
(139 citation statements)
references
References 21 publications
3
129
1
6
Order By: Relevance
“…Also our previous study showed that PAC with uracil -tegafur conferred a survival benefit for patients with resected stage I adenocarcinoma of the lung (Kato et al, 2004). Also, meta-analysis of PAC with tegafur -uracil supported this result (Hamada et al, 2005). However, even though a significant difference was found in this study, the 5-year-survival rate benefit of this therapy was 11.5% for stage IB adenocarcinoma (Kato et al, 2004).…”
Section: Discussionsupporting
confidence: 52%
“…Also our previous study showed that PAC with uracil -tegafur conferred a survival benefit for patients with resected stage I adenocarcinoma of the lung (Kato et al, 2004). Also, meta-analysis of PAC with tegafur -uracil supported this result (Hamada et al, 2005). However, even though a significant difference was found in this study, the 5-year-survival rate benefit of this therapy was 11.5% for stage IB adenocarcinoma (Kato et al, 2004).…”
Section: Discussionsupporting
confidence: 52%
“…26,27 It is noteworthy that adjuvant chemotherapy with uracil-tegafur (UFT), an oral 5-FU derivative, reportedly improved survival significantly among Japanese patients with completely resected NSCLC, as reported in several trials and in a meta-analysis. 28,29 Moreover, in a Japanese trial, adjuvant UFT was effective only in patients with early-stage adenocarcinoma, and no significant benefit to survival was reported in patients with squamous cell carcinoma. 30 In all of the studies mentioned above, TS activity was not assessed; however, the results of the current study provide a rational explanation for the better outcome and response to chemotherapy among patients with adenocarcinoma of the lung who received TS-inhibitor regimens.…”
Section: Discussionmentioning
confidence: 99%
“…A meta-analysis performed by Hamada et al assessed the difference in efficacy between chemotherapy with Tegafur-Uracil (UFT) and the standard postoperative adjuvant chemotherapy regimen for completely resected NSCLC. This meta-analysis showed that postoperative adjuvant chemotherapy with UFT significantly improved 5-and 7-year survival (Hamada et al 2005). Several recent phase II clinical trials suggested that S-1-based chemotherapy showed favorable clinical efficacy and mild toxicities, regardless of treatment with single agent S-1 or an S-1-based combination regimen (Kawahara et al 2001;Yanagihara et al 2010).…”
Section: Introductionmentioning
confidence: 91%